MDS

A cancer survivor explains how the new treatments coming out for all types of cancer give her hope. “If we are diagnosed today, a cure or remission may come out next week or next month, or next year to give us additional time to live,” she writes.

A phase 2 trial of aspacytarabine (BST-236) was initiated in patients with AML and MDS.

A cancer survivor explains why each person experiences cancer differently – from side effects to treatments and more.

A patient with MDS writes about facing fears during the treatment journey.

How are myelodysplastic syndromes diagnosed and staged? What causes them? An expert from Moffit Cancer Center offers insight.

The FDA will expedite the development and review of the drug combination to treat untreated intermediate- high- and very high-risk myelodysplastic syndrome.

Previously, Vidaza alone showed poor response rates for patients with TP53-mutated, myelodysplastic syndromes and acute myeloid leukemia, but adding the novel agent eprenetapopt improved response rates and overall survival in this patient population.

Before I became ill, I had wondered why anyone would want to work in a field where they knew people might die. But after meeting some incredible nurses during my cancer journey, I now know why.

The Food and Drug Administration approved the oral combination of Inquovi (Dacogen [decitabine] and cedazuridine) for certain adult patients with myelodysplastic syndromes (MDS).

A cancer survivor describes the changes of going for treatment during the pandemic.

A cancer survivor often contemplates which is the lesser of two evils – cancer or treatment?

What do erasers, drawings, cancer and life all have in common? More than you might think.

Sometimes starting a new chapter in life can be good for cancer survivors.